Journey Medical (DERM) Competitors $7.11 +0.01 (+0.14%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DERM vs. FBIO, AUTL, STOK, URGN, PHAT, RLAY, ABUS, TNGX, CDXC, and DNTHShould you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Fortress Biotech (FBIO), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector. Journey Medical vs. Its Competitors Fortress Biotech Autolus Therapeutics Stoke Therapeutics Urogen Pharma Phathom Pharmaceuticals Relay Therapeutics Arbutus Biopharma Tango Therapeutics ChromaDex Dianthus Therapeutics Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Does the media prefer DERM or FBIO? In the previous week, Journey Medical had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 1 mentions for Journey Medical and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Journey Medical's score of -0.38 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Overall Sentiment Journey Medical Neutral Fortress Biotech Neutral Do institutionals & insiders hold more shares of DERM or FBIO? 7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 27.9% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is DERM or FBIO more profitable? Journey Medical has a net margin of -14.76% compared to Fortress Biotech's net margin of -71.24%. Journey Medical's return on equity of -52.03% beat Fortress Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-14.76% -52.03% -11.28% Fortress Biotech -71.24%-4,712.53%-27.67% Which has preferable earnings & valuation, DERM or FBIO? Journey Medical has higher earnings, but lower revenue than Fortress Biotech. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.13M2.95-$14.67M-$0.39-18.23Fortress Biotech$57.67M0.98-$46M-$2.23-0.86 Do analysts prefer DERM or FBIO? Journey Medical presently has a consensus price target of $9.50, suggesting a potential upside of 33.61%. Fortress Biotech has a consensus price target of $21.00, suggesting a potential upside of 999.48%. Given Fortress Biotech's higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, DERM or FBIO? Journey Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. SummaryJourney Medical beats Fortress Biotech on 8 of the 15 factors compared between the two stocks. Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DERM vs. The Competition Export to ExcelMetricJourney MedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.40M$2.43B$5.53B$9.03BDividend YieldN/A1.78%5.24%4.07%P/E Ratio-18.238.7527.1920.03Price / Sales2.95641.55414.39108.98Price / CashN/A21.7726.2128.59Price / Book7.814.497.925.55Net Income-$14.67M$31.26M$3.17B$248.49M7 Day Performance-0.97%1.60%2.18%5.37%1 Month Performance-3.79%2.46%1.25%6.63%1 Year Performance36.47%-0.33%33.90%21.20% Journey Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DERMJourney Medical1.8705 of 5 stars$7.11+0.1%$9.50+33.6%+36.3%$165.40M$56.13M-18.2390Analyst DowngradeFBIOFortress Biotech2.1005 of 5 stars$1.91+1.6%$21.00+999.5%+6.1%$55.59M$57.67M-0.86170AUTLAutolus Therapeutics2.1039 of 5 stars$2.26-4.6%$9.32+312.4%-31.3%$630.76M$10.12M-2.57330STOKStoke Therapeutics3.985 of 5 stars$11.69+1.8%$23.20+98.5%-12.5%$626.77M$36.56M14.80100URGNUrogen Pharma4.4473 of 5 stars$13.49-0.7%$32.86+143.6%-15.1%$626.14M$90.40M-4.24200Analyst ForecastPHATPhathom Pharmaceuticals3.4413 of 5 stars$8.66-2.9%$17.50+102.1%-14.9%$622.74M$55.25M-1.65110RLAYRelay Therapeutics2.7682 of 5 stars$3.55-2.2%$17.67+397.7%-43.1%$622.34M$10.01M-1.59330Positive NewsABUSArbutus Biopharma1.4257 of 5 stars$3.14-3.1%$5.50+75.2%+3.7%$620.55M$6.17M-7.6690TNGXTango Therapeutics2.2074 of 5 stars$5.43-4.7%$12.20+124.7%-33.5%$617.85M$40.99M-4.4590CDXCChromaDex3.1726 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120DNTHDianthus Therapeutics1.794 of 5 stars$18.25-3.2%$53.00+190.4%-24.2%$606.22M$6.24M-6.3480Analyst Revision Related Companies and Tools Related Companies Fortress Biotech Competitors Autolus Therapeutics Competitors Stoke Therapeutics Competitors Urogen Pharma Competitors Phathom Pharmaceuticals Competitors Relay Therapeutics Competitors Arbutus Biopharma Competitors Tango Therapeutics Competitors ChromaDex Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DERM) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DERM Stock Alerts